文献速递乳腺乳腺X线MRUSPET

癌症影像学机遇:筛查中的风险适应性乳腺影像

Opportunities in cancer imaging: risk-adapted breast imaging in screening.
PubMed 文献 · Clin Radiol · 2021-04-02

文章综述了英国基于风险分层的乳腺筛查策略,指出通过问卷、乳腺密度和多基因风险评分可将人群分层,乳腺X线摄影在BI-RADS D类致密乳腺中敏感度仅60%,补充超声、CESM、ABB-MRI或闪烁乳腺摄影可提高癌症检出。

要点

  • BI-RADS D类致密乳腺女性乳腺癌风险为2.5-4倍,乳腺X线摄影敏感度仅60%。
  • 补充超声可提高癌症检出率,减少晚期 interval 癌和下一轮筛查癌。
  • CESM和ABB-MRI在致密乳腺中检测癌症更有效,闪烁乳腺摄影是可行替代。

关键影像表现/征象

  • 乳腺X线摄影在BI-RADS D类致密乳腺中敏感度低,仅60%。
  • 补充超声可提高癌症检出率并减少晚期 interval 癌和下一轮筛查癌。
  • CESM和ABB-MRI在致密乳腺中检测癌症比乳腺X线更有效。
  • 闪烁乳腺摄影对致密乳腺或乳腺癌治疗后瘢痕随访是可行替代。

诊断标准与关键数值

  • 终生风险>30%的女性每年接受MRI和乳腺X线,部分中风险女性每年乳腺X线。
  • 通过问卷、乳腺密度和多基因风险评分分层:最低20%风险人群发生<4%癌症,最高4%风险人群发生18%癌症。
  • BI-RADS D类致密乳腺女性乳腺癌风险为2.5-4倍,乳腺X线敏感度60%。

临床应用与阅片要点

  • 对致密乳腺(BI-RADS D)女性,应关注乳腺X线敏感度下降,考虑补充超声、CESM或ABB-MRI。
  • 补充筛查需权衡降低II期癌和成本效果,大规模试验证据尚需积累。

局限性

  • 综述未报告系统检索范围和纳入文献数量。
  • 补充影像的成本效果和降低II期癌的证据需大规模试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

In the UK, women between 50-70 years are invited for 3-yearly mammography screening irrespective of their likelihood of developing breast cancer. The only risk adaption is for women with >30% lifetime risk who are offered annual magnetic resonance imaging (MRI) and mammography, and annual mammography for some moderate-risk women. Using questionnaires, breast density, and polygenic risk scores, it is possible to stratify the population into the lowest 20% risk, who will develop <4% of cancers and the top 4%, who will develop 18% of cancers. Mammography is a good screening test but has low sensitivity of 60% in the 9% of women with the highest category of breast density (BIRADS D) who have a 2.5- to fourfold breast cancer risk. There is evidence that adding ultrasound to the screening mammogram can increase the cancer detection rate and reduce advanced stage interval and next round cancers. Similarly, alternative tests such as contrast-enhanced mammography (CESM) or abbreviated MRI (ABB-MRI) are much more effective in detecting cancer in women with dense breasts. Scintimammography has been shown to be a viable alternative for dense breasts or for follow-up in those with a personal history of breast cancer and scarring as result of treatment. For supplemental screening to be worthwhile in these women, new technologies need to reduce the number of stage II cancers and be cost effective when tested in large scale trials. This article reviews the evidence for supplemental imaging and examines whether a risk-stratified approach is feasible.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Gilbert FJ, Hickman SE, Baxter GC, et al. Opportunities in cancer imaging: risk-adapted breast imaging in screening. Clin Radiol. 2021. PMID: 33820637. doi:10.1016/j.crad.2021.02.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。